RANI – rani therapeutics holdings, inc. - class a (US:NASDAQ)
Stock Stats
News
Rani Therapeutics to Participate in May Investor Conferences
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its price target raised by analysts at BTIG Research from $7.00 to $14.00. They now have a "buy" rating on the stock.
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024 [Yahoo! Finance]
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its price target raised by analysts at HC Wainwright from $12.00 to $13.00. They now have a "buy" rating on the stock.
Form 10-Q Rani Therapeutics Holdin For: Mar 31
Form 8-K Rani Therapeutics Holdin For: May 06
Form ARS Rani Therapeutics Holdin For: Dec 31
Form DEFA14A Rani Therapeutics Holdin
Form DEF 14A Rani Therapeutics Holdin For: May 29
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.